BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia - Nasdaq

Submitted by Anonymous (not verified) on Mon, 07/22/2019 - 10:00

BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia  NasdaqStatistically significant mean reduction in PEC score at two hours compared to placebo following a single dose of 180 mcg (p. Approximately 90% of.